CAS
SGMO

Coppell Advisory Solutions’s SANGAMO THERAPEUTICS INC SGMO Stock Holding History

Coppell Advisory Solutions’s Portfolio SGMO Stock Details SGMO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-200
Closed -$468 – 1579
2024
Q4 		$468 Hold
200
– – ﹤0.01% 1764
2024
Q3 		$173 Hold
200
– – ﹤0.01% 1743
2024
Q2 		$72 Buy
+200
New +$108 ﹤0.01% 1740
2023
Q4 		$109 Hold
200
– – ﹤0.01% 1639
2023
Q3 		$628 Hold
200
– – ﹤0.01% 986
2023
Q2 		$250 Buy
+200
New +$273 ﹤0.01% 1302
2023
Q1 		– Sell
-200
Closed -$628 – 913
2022
Q4 		$628 Buy
+200
New +$776 ﹤0.01% 992

Other funds holding SGMO

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Coppell Advisory Solutions's SGMO Position: Q1 2025 in Review

Coppell Advisory Solutions sold out of SANGAMO THERAPEUTICS INC (SGMO) in Q1 2025, closing a stake of 200 shares — an estimated $468 sold.

Coppell Advisory Solutions first reported a position in SGMO in Q4 2022 and held it in 7 quarters. The position peaked at $628 in Q3 2023. 122 funds tracked by Wall St. Rank hold SGMO as of Q1 2025.

  • Coppell Advisory Solutions reported no remaining SANGAMO THERAPEUTICS INC position as of Q1 2025 after selling out during the quarter.
  • Coppell Advisory Solutions sold 200 SANGAMO THERAPEUTICS INC shares in Q1 2025, an estimated $468.
  • Coppell Advisory Solutions first reported a position in SANGAMO THERAPEUTICS INC in Q4 2022 and held it in 7 quarters.
  • Coppell Advisory Solutions's SANGAMO THERAPEUTICS INC position peaked at $628 in Q3 2023.
  • 122 funds tracked by Wall St. Rank held SANGAMO THERAPEUTICS INC as of Q1 2025.

Based on Coppell Advisory Solutions's 13F filing for Q1 2025, filed 16 May 2025.